Ovuclon50 mg

Clomiphene citrate is used for the treatment of ovulatory dysfunction in women desiring pregnancy who have demonstrated adequate endogenous oestrogen levels. It is considered a first-line treatment for anovulatory infertility, including in women with polycystic ovary syndrome (PCOS), and is used to induce ovulation in normally oestrogenized, anovulatory women. It is also used off-label to induce spermatogenesis in certain cases of male infertility, under specialist guidance.

Contains Ovuclon 50 mg as the active ingredient, available as oral tablets, commonly in a 50 mg strength.

Clomiphene citrate is an oral fertility medicine used to stimulate ovulation in women who are not ovulating regularly, most commonly due to polycystic ovary syndrome or other causes of ovulatory dysfunction. It works by blocking oestrogen's usual feedback signal to the brain, which tricks the body into producing more of the hormones that stimulate the ovary to develop and release an egg. While effective and widely used, clomiphene increases the risk of multiple pregnancy (mainly twins) and, less commonly, ovarian hyperstimulation syndrome, and treatment is generally limited to a defined number of cycles with careful monitoring between courses.

Therapeutic Class: Ovulatory Stimulant (Selective Estrogen Receptor Modulator)

Clomiphene citrate is capable of interacting with oestrogen receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix, acting as an oestrogen antagonist in some tissues while retaining some weak oestrogenic activity in others. By blocking oestrogen's normal negative feedback on the hypothalamus and pituitary, it increases the release of gonadotropin-releasing hormone, which in turn increases follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release, stimulating ovarian follicle development and, ultimately, ovulation.

• Taken orally, once daily, for 5 consecutive days, typically starting on day 5 of the menstrual cycle
• Can be taken with or without food
• Timing of intercourse or insemination should coincide with expected ovulation, typically 5-10 days after completing the 5-day course, as guided by your fertility specialist
• Ovulation is generally confirmed using basal body temperature charting, ultrasound monitoring, or other tests as directed by your doctor

The following should be assessed by a healthcare professional before combining with clomiphene:

• Gonadotropins (such as hMG or FSH), when combined with clomiphene in some protocols: requires careful monitoring, given an increased risk of multiple follicular development and ovarian hyperstimulation syndrome.
• Dexamethasone, when added to clomiphene in some protocols (particularly for women with elevated androgen levels): used deliberately in some specialist regimens to improve ovulation induction, under close monitoring.

Common side effects

• Hot flushes
• Abdominal or pelvic discomfort, bloating
• Breast tenderness
• Nausea, vomiting
• Headache
• Visual disturbances (blurring, spots, or flashes) - report promptly, since these can occasionally persist

Serious side effects (require prompt medical attention)

• Ovarian hyperstimulation syndrome (OHSS): a distinct medical event from simple, uncomplicated ovarian enlargement; symptoms include severe abdominal pain, significant bloating, rapid weight gain, nausea, vomiting, and reduced urination, and can be serious in severe cases - seek medical attention promptly if these occur.
• Multiple pregnancy: clomiphene increases the risk of a multiple pregnancy (mainly twins), which carries higher obstetric risk than a singleton pregnancy.
• Persistent visual symptoms (blurred vision, scotomata/visual spots) - discontinue treatment and seek prompt ophthalmologic evaluation, since visual effects, while often reversible, may occasionally be irreversible with continued use.
• Ovarian enlargement or cyst formation, requiring evaluation before starting a further treatment cycle.

Pregnancy

Clomiphene citrate is contraindicated during pregnancy, since treatment offers no benefit once pregnancy has occurred and animal studies have shown potential fetal risk; a pregnancy test to exclude pregnancy is generally performed before starting each treatment cycle.

Breastfeeding

Clomiphene is not indicated for use during breastfeeding, since it is used specifically to induce ovulation in women trying to conceive; discuss any concerns with your treating specialist.

• Multiple pregnancy risk: clomiphene increases the chance of a multiple (usually twin) pregnancy; this should be discussed as part of informed treatment planning.
• Ovarian hyperstimulation syndrome: use the lowest effective dose and duration to reduce this risk, and seek prompt medical attention for symptoms such as severe abdominal pain, bloating, or reduced urination.
• Visual disturbances: discontinue treatment if visual symptoms occur and seek an ophthalmologic evaluation, particularly with prolonged or repeated use, since visual effects may occasionally be irreversible.
• Evaluate for pregnancy, ovarian enlargement, or cyst formation before starting each new treatment cycle.
• If ovulation does not occur after 3 courses, or 3 ovulatory cycles occur without pregnancy, treatment should generally be reassessed rather than continued indefinitely.
• Increased body mass index is consistently associated with a reduced response to clomiphene; weight optimization, where relevant, can improve treatment outcomes.

Overdose may cause exaggerated known effects, including nausea, vomiting, hot flushes, visual disturbances, and an increased risk of ovarian hyperstimulation. Suspected significant overdose should be evaluated by a healthcare professional; treatment is generally supportive, with monitoring for signs of ovarian hyperstimulation.

Store at room temperature, protected from moisture and light, as directed on the product label. Keep out of reach of children.

• Polycystic ovary syndrome: A common and appropriate use of clomiphene; lower doses and durations are generally preferred in this population to reduce ovarian hyperstimulation risk.
• Increased body mass index: Associated with reduced clomiphene response; weight management may be recommended as part of overall treatment.
• Hepatic impairment: Contraindicated, given the risk of altered drug metabolism and clearance.

Each treatment cycle involves 5 days of dosing, with treatment generally limited to a maximum of about 6 cycles overall; if ovulation does not occur after 3 courses, or pregnancy does not result after 3 ovulatory cycles, the treating specialist will generally reassess the diagnosis and treatment approach rather than continuing clomiphene indefinitely.

Drug Class: Selective oestrogen receptor modulator (triphenylethylene derivative)

Clomiphene works by blocking oestrogen receptors in the hypothalamus, which normally sense circulating oestrogen levels and signal the pituitary gland to reduce hormone output once oestrogen is adequate. By blocking this feedback signal, clomiphene causes the body to interpret oestrogen levels as low, prompting the pituitary to release more FSH and LH, which stimulates the ovary to develop one or more follicles and, in a successful cycle, release an egg (ovulation).

Clomiphene citrate is not indicated for use in children, as it is specifically used for ovulation induction in adult women (and, off-label, spermatogenesis induction in adult men) as part of fertility treatment.